Cvijic Christine Mikail 4
4 · Neurogene Inc. · Filed May 8, 2026
Research Summary
AI-generated summary of this filing
Neurogene (NGNE) President/CFO Christine Cvijic Sells Shares
What Happened
Christine Mikail Cvijic, President, Chief Financial Officer and a director of Neurogene Inc., sold a total of 9,600 shares in two open‑market transactions on May 6, 2026. The sales consisted of 4,800 shares at a weighted average price of $32.44 (proceeds $155,692) and 4,800 shares at a weighted average price of $30.07 (proceeds $144,351), for total proceeds of approximately $300,043. These were sales (not purchases) and were reported on a Form 4 filed May 8, 2026.
Key Details
- Transaction date: May 6, 2026 (reported May 8, 2026) — timely filing.
- Lots: 4,800 shares @ $32.44 (proceeds $155,692); 4,800 shares @ $30.07 (proceeds $144,351); total = 9,600 shares for ~$300,043.
- Price ranges (multiple trades): the $30.07 weighted average reflects trades in the $30.00–$30.31 range; the $32.44 weighted average reflects trades in the $32.02–$32.695 range. Reporting person can provide per‑trade breakdown on request (per footnotes).
- Plan/authority: Sales were effected pursuant to a 10b5‑1 trading plan adopted by Ms. Cvijic on August 18, 2025; the shares sold were held jointly by Ms. Cvijic and her spouse, David Cvijic.
- Holdings/awards noted in filing: unvested restricted stock units totaling 46,168 (10,635 vesting March 13, 2027; 13,533 vesting in equal installments March 26, 2027 & 2028; 22,000 vesting in equal installments Feb 20, 2027–2029). The filing also notes 9,600 shares held jointly by Ms. Cvijic and her spouse.
Context
These sales were executed under a pre‑arranged 10b5‑1 plan, which is commonly used by insiders to sell shares at predetermined times and is generally considered routine. Sales do not necessarily indicate negative views about the company; they can reflect diversification, tax planning, or other personal reasons. For retail investors, purchases by insiders tend to be more informative about confidence in the business, while planned sales like this are common.
Insider Transaction Report
- Sale
Common Stock
[F1][F4][F3]2026-05-06$32.44/sh−4,800$155,692→ 93,640 total - Sale
Common Stock
[F1][F2][F3]2026-05-06$30.07/sh−4,800$144,351→ 98,440 total
Footnotes (4)
- [F1]The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.31, inclusive. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 9,600 are held jointly by the reporting person and her spouse, David Cvijic.
- [F4]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.02 to $32.695, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.